9 METERS BIOPHARMA, INC.

2020 Q1 Form 10-Q Financial Statement

#000155198620000153 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.670M $11.49M
YoY Change -76.76% -11.48%
Cash & Equivalents $2.668M $11.49M
Short-Term Investments
Other Short-Term Assets $570.0K $980.0K
YoY Change -41.84% 292.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.231M $12.47M
YoY Change -74.1% -5.7%
LONG-TERM ASSETS
Property, Plant & Equipment $20.14K $29.96K
YoY Change -32.77% -42.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K
YoY Change 0.0% 0.0%
Total Long-Term Assets $54.70K $117.5K
YoY Change -53.46% 104.25%
TOTAL ASSETS
Total Short-Term Assets $3.231M $12.47M
Total Long-Term Assets $54.70K $117.5K
Total Assets $3.286M $12.59M
YoY Change -73.9% -5.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.075M $3.929M
YoY Change 29.19% 94.01%
Accrued Expenses $4.848M $897.3K
YoY Change 440.29% 15035.88%
Deferred Revenue
YoY Change
Short-Term Debt $4.300M $3.740M
YoY Change 14.97% 9.68%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.84M $10.94M
YoY Change 44.7% 101.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.00K
YoY Change
Total Long-Term Liabilities $0.00 $30.00K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.84M $10.94M
Total Long-Term Liabilities $0.00 $30.00K
Total Liabilities $15.84M $10.97M
YoY Change 44.36% 101.71%
SHAREHOLDERS EQUITY
Retained Earnings -$74.17M -$47.95M
YoY Change 54.67% 39.74%
Common Stock $4.133K $3.107K
YoY Change 33.02% 20.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.55M $1.618M
YoY Change
Total Liabilities & Shareholders Equity $3.286M $12.59M
YoY Change -73.9% -5.23%

Cashflow Statement

Concept 2020 Q1 2019 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96251341.8 shares
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4143269 USD
CY2020Q1 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4284110 USD
CY2019Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2020Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2019Q1 nmtr Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities
AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities
1970000 USD
CY2020Q1 nmtr Capital Stock Authorized
CapitalStockAuthorized
360000000 shares
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
CY2019Q2 nmtr Class Of Warrant Or Right Purchase Price Of Each Additional Warrant
ClassOfWarrantOrRightPurchasePriceOfEachAdditionalWarrant
0.125
CY2019Q2 nmtr Class Of Warrant Or Right Restriction Period
ClassOfWarrantOrRightRestrictionPeriod
P45D
CY2018Q3 nmtr Estimated Clinical Trial Data Management Fee
EstimatedClinicalTrialDataManagementFee
1100000 USD
CY2019Q1 nmtr Gain Losson Extinguishmentof Derivative Liability
GainLossonExtinguishmentofDerivativeLiability
370000 USD
CY2020Q1 nmtr Gain Losson Extinguishmentof Derivative Liability
GainLossonExtinguishmentofDerivativeLiability
0 USD
CY2019Q1 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
151137 USD
CY2020Q1 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
0 USD
CY2019Q1 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
1281000 USD
CY2020Q1 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
370000 USD
CY2020Q1 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 plan
CY2017Q4 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
60000 USD
CY2018Q4 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
CY2014 nmtr Royalties Payment Expiration Requirement
RoyaltiesPaymentExpirationRequirement
P10Y
CY2018Q3 nmtr Saleof Stock Shares Issuable Upon Exerciseof Warrant
SaleofStockSharesIssuableUponExerciseofWarrant
2051771 shares
CY2018Q3 nmtr Saleof Stock Shelf Registration Maximum Equity Offering Price
SaleofStockShelfRegistrationMaximumEquityOfferingPrice
175000000 USD
CY2020Q1 nmtr Stock Issued During Period Shares Warrant Exchange
StockIssuedDuringPeriodSharesWarrantExchange
1847308.8 shares
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
74803 USD
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
481024 USD
CY2018Q3 nmtr Saleof Stock Stockholders Aggregate Shares Availableforsale
SaleofStockStockholdersAggregateSharesAvailableforsale
13990403 shares
CY2020Q1 nmtr Severance Costs Equal Installment Period
SeveranceCostsEqualInstallmentPeriod
P12M
CY2018Q1 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
CY2018Q1 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15800000 shares
CY2019Q4 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
3593714.4 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15786020 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21200000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21247679 shares
CY2019Q4 us-gaap Assets
Assets
5296816 USD
CY2020Q1 us-gaap Assets
Assets
3285649 USD
CY2020Q1 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
1847309 shares
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5222984 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
3230954 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4592932 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2667743 USD
CY2020Q1 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
690839 USD
CY2019Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5728900 USD
CY2020Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
690839 USD
CY2019Q4 nmtr Warrant Liability Current
WarrantLiabilityCurrent
2637500 USD
CY2020Q1 nmtr Warrant Liability Current
WarrantLiabilityCurrent
1058700 USD
CY2019Q2 nmtr Warrants And Rights Outstanding Exercise Commencement Period
WarrantsAndRightsOutstandingExerciseCommencementPeriod
P6M
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3890094 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5075478 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4747751 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4847823 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60946816 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61613470 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
526000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
276000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
319819 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
300000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
526000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
276000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11494894 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2667743 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5765994 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1925189 USD
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2020Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.13
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
3897010 shares
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25141814 shares
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25960437 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39477667 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41324976 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39477667 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39477667 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41324976 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41324976 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
3948 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
4133 USD
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3184655 USD
CY2020Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4302875 USD
CY2019Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1049166 USD
CY2019Q1 us-gaap Depreciation
Depreciation
5139 USD
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P24M
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5296816 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q1 us-gaap Depreciation
Depreciation
5284 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
574332 USD
CY2019Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
471000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
530760 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1200000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-857000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1578800 USD
CY2020Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1536200 USD
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3045500 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1498700 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3285649 USD
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
338000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
408000 USD
CY2020Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
440000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3114495 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1669807 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4434765 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3603001 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
163564 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1185384 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
70928 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
100072 USD
CY2019Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-101000 USD
CY2020Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-338000 USD
CY2019Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-101624 USD
CY2020Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
298096 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-66841 USD
CY2019Q1 us-gaap Interest Expense
InterestExpense
427245 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
572985 USD
CY2019Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
35139 USD
CY2020Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
81972 USD
CY2019Q1 us-gaap Interest Income Other
InterestIncomeOther
26456 USD
CY2020Q1 us-gaap Interest Income Other
InterestIncomeOther
12815 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
418927 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
54578 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2020Q1 us-gaap Interest Payable Current
InterestPayableCurrent
81972 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
30000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1023 USD
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2017Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14910830 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15835825 USD
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2020Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3600000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10003740 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
707196 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4237746 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2632385 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4434765 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603001 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-121955 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1356630 USD
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4312810 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4959631 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4312810 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4959631 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
15000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
28977 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42830 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28977 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42830 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28977 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30150 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32953 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2019Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57000 USD
CY2020Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
23000 USD
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
168682 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
555052 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
488211 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11475255 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9700000 USD
CY2019Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7900000 USD
CY2019Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
CY2020Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20138 USD
CY2019Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
6245833 USD
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1469804 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1198315 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2598985 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70564778 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74167779 USD
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4181068 shares
CY2019Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4318272 shares
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1847309 shares
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
5000 USD
CY2019Q1 us-gaap Severance Costs1
SeveranceCosts1
300000 USD
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
526000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
276000 USD
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.33
CY2019Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.025
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11475255 USD
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3659064 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1617607 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-12550176 USD
CY2019Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27252278 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41162296 shares
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets and management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0001551986-20-000153-index-headers.html Edgar Link pending
0001551986-20-000153-index.html Edgar Link pending
0001551986-20-000153.txt Edgar Link pending
0001551986-20-000153-xbrl.zip Edgar Link pending
ex311q12020.htm Edgar Link pending
ex312q12020.htm Edgar Link pending
ex321q12020.htm Edgar Link pending
ex322q12020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inntq1202010-q.htm Edgar Link pending
nmtr-20200331.xml Edgar Link completed
nmtr-20200331.xsd Edgar Link pending
nmtr-20200331_cal.xml Edgar Link unprocessable
nmtr-20200331_def.xml Edgar Link unprocessable
nmtr-20200331_lab.xml Edgar Link unprocessable
nmtr-20200331_pre.xml Edgar Link unprocessable
pipelinegraphicjp.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending